ALNY Relative Valuation
ALNY's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ALNY is overvalued; if below, it's undervalued.
Historical Valuation
Alnylam Pharmaceuticals Inc (ALNY) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -44.69. The fair price of Alnylam Pharmaceuticals Inc (ALNY) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 473.29 USD , Alnylam Pharmaceuticals Inc is Undervalued By Fair.
Relative Value
Fair Zone
+Inf-+Inf
Current Price：473.29
Fair
Undervalued
70.64
PE
1Y
3Y
5Y
Trailing
Forward
51.61
EV/EBITDA
Alnylam Pharmaceuticals Inc. (ALNY) has a current EV/EBITDA of 51.61. The 5-year average EV/EBITDA is -7427.25. The thresholds are as follows: Strongly Undervalued below -124449.31, Undervalued between -124449.31 and -65938.28, Fairly Valued between 51083.78 and -65938.28, Overvalued between 51083.78 and 109594.81, and Strongly Overvalued above 109594.81. The current Forward EV/EBITDA of 51.61 falls within the Historic Trend Line -Fairly Valued range.
53.30
EV/EBIT
Alnylam Pharmaceuticals Inc. (ALNY) has a current EV/EBIT of 53.30. The 5-year average EV/EBIT is -75.62. The thresholds are as follows: Strongly Undervalued below -1579.01, Undervalued between -1579.01 and -827.31, Fairly Valued between 676.08 and -827.31, Overvalued between 676.08 and 1427.78, and Strongly Overvalued above 1427.78. The current Forward EV/EBIT of 53.30 falls within the Historic Trend Line -Fairly Valued range.
12.08
PS
Alnylam Pharmaceuticals Inc. (ALNY) has a current PS of 12.08. The 5-year average PS is 15.55. The thresholds are as follows: Strongly Undervalued below 7.54, Undervalued between 7.54 and 11.55, Fairly Valued between 19.55 and 11.55, Overvalued between 19.55 and 23.55, and Strongly Overvalued above 23.55. The current Forward PS of 12.08 falls within the Historic Trend Line -Fairly Valued range.
34.23
P/OCF
Alnylam Pharmaceuticals Inc. (ALNY) has a current P/OCF of 34.23. The 5-year average P/OCF is 103.09. The thresholds are as follows: Strongly Undervalued below -587.15, Undervalued between -587.15 and -242.03, Fairly Valued between 448.21 and -242.03, Overvalued between 448.21 and 793.33, and Strongly Overvalued above 793.33. The current Forward P/OCF of 34.23 falls within the Historic Trend Line -Fairly Valued range.
56.36
P/FCF
Alnylam Pharmaceuticals Inc. (ALNY) has a current P/FCF of 56.36. The 5-year average P/FCF is -71.61. The thresholds are as follows: Strongly Undervalued below -1773.50, Undervalued between -1773.50 and -922.56, Fairly Valued between 779.33 and -922.56, Overvalued between 779.33 and 1630.27, and Strongly Overvalued above 1630.27. The current Forward P/FCF of 56.36 falls within the Historic Trend Line -Fairly Valued range.
Alnylam Pharmaceuticals Inc (ALNY) has a current Price-to-Book (P/B) ratio of 266.68. Compared to its 3-year average P/B ratio of -1083.50 , the current P/B ratio is approximately -124.61% higher. Relative to its 5-year average P/B ratio of -645.02, the current P/B ratio is about -141.34% higher. Alnylam Pharmaceuticals Inc (ALNY) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -0.50%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -1.71% , the current FCF yield is about -100.00% lower.
262.20
P/B
Median3y
-1083.50
Median5y
-645.02
0.35
FCF Yield
Median3y
-0.50
Median5y
-1.71
Competitors Valuation Multiple
The average P/S ratio for ALNY's competitors is 2.50, providing a benchmark for relative valuation. Alnylam Pharmaceuticals Inc Corp (ALNY) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of 149.35%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of ALNY increased by 97.76% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 500.92M to 1.25B.
The secondary factor is the P/E Change, contributed 138.67%to the performance.
Overall, the performance of ALNY in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
FAQ
Is Alnylam Pharmaceuticals Inc (ALNY) currently overvalued or undervalued?
What is Alnylam Pharmaceuticals Inc (ALNY) fair value?
How does ALNY's valuation metrics compare to the industry average?
What is the current P/B ratio for Alnylam Pharmaceuticals Inc (ALNY) as of Dec 05 2025?
What is the current FCF Yield for Alnylam Pharmaceuticals Inc (ALNY) as of Dec 05 2025?
What is the current Forward P/E ratio for Alnylam Pharmaceuticals Inc (ALNY) as of Dec 05 2025?